HYPERION DEFI, INC. (HYPD) - Dilution Analysis

10-Q filing | 15.2M shares outstanding

8-K filing: The Company issued and Chardan Capital Markets, LLC purchased 132,249 shares of common stock for approximately $0.4 million in net proceeds following the exercise of an option. ($0.4M proceeds)

8-K filing: Hyperion DeFi, Inc. entered into an underwriting agreement with Chardan Capital Markets, LLC for the issuance and sale of 2,777,778 shares of common stock at $3.60 per share, with an option for the Underwriter to purchase an additional 416,666 shares. ($10.0M proceeds)

8-K filing: On January 5, 2026, 100,000 shares of Series A Preferred Stock were converted into 300,000 shares of common stock of Hyperion DeFi, Inc. for no additional consideration.

S-3 filing: The company is filing an S-3 to register the offering of common stock, preferred stock, and debt securities, separately or in combination, for a total aggregate amount of $1,000,000,000.

10-Q filing | 1.5M shares outstanding

10-Q filing | 1.5M shares outstanding

S-3 filing: This prospectus relates to the offer and sale from time to time, by the selling securityholders identified in this prospectus, of up to 50,770,667 shares of common stock of Hyperion DeFi, Inc.

10-Q filing | 1.5M shares outstanding

S-3 filing: This prospectus relates to the offer and sale from time to time, by the selling securityholders, of up to 6,370,387 shares of the common stock of Eyenovia, Inc.

10-K filing | 2.8M shares outstanding

8-K filing: Stock split 80-for-1 | Outstanding: 45,553,026 → 3,644,242,080

8-K filing: Eyenovia, Inc. completed the exercise of existing warrants for 15,769,445 shares of common stock, receiving gross proceeds of approximately $1.0 million and issued new warrants to purchase up to 200% of the exercised shares. ($1.0M proceeds)

8-K filing: Eyenovia, Inc. entered into a securities purchase agreement to sell 11,000,000 shares of common stock, pre-funded warrants to purchase up to 9,085,025 shares of common stock, and warrants to purchase up to 40,170,050 shares of common stock in a registered direct offering, with expected gross proceeds of approximately $1.95 million. ($1.95M proceeds)

8-K filing: Eyenovia, Inc. completed a registered direct offering of 9,000,000 shares of common stock, pre-funded warrants to purchase up to 3,081,785 shares of common stock, and warrants to purchase up to 24,163,570 shares of common stock, with gross proceeds expected to be approximately $1.3 million. ($1.3M proceeds)

8-K filing: Eyenovia, Inc. issued 1,901,733 shares of common stock to lenders at a price of approximately $0.1052 per share under a Subscription Agreement.

10-Q filing | 45.6M shares outstanding

S-3 filing: The filing is for a shelf registration to offer and sell up to $100,000,000 of common stock, preferred stock and debt securities from time to time and an at-the-market offering of common stock up to $25,000,000.

8-K filing: Eyenovia, Inc. completed a registered direct offering of 8,630,000 shares of common stock, pre-funded warrants to purchase up to 65,653 shares of common stock, and warrants to purchase up to 8,695,653 shares of common stock, with gross proceeds expected to be approximately $4.0 million. ($4.0M proceeds)

8-K filing: Eyenovia, Inc. agreed to sell 12,850,000 shares of common stock at $0.40 per share to certain institutional and accredited investors, with aggregate gross proceeds expected to be approximately $5.14 million, to fund commercialization activities, complete a clinical study, and for working capital and general corporate purposes. ($5.14M proceeds)

10-Q filing | 45.6M shares outstanding

8-K filing: Eyenovia, Inc. entered into a securities purchase agreement to sell 7,575,757 shares of common stock and warrants in a registered direct offering, with gross proceeds expected to be approximately $5.0 million. ($5.0M proceeds)

10-Q filing | 46.6M shares outstanding

8-K filing: Eyenovia, Inc. filed a prospectus supplement to its registration statement on Form S-3 for the sale and issuance of 3,223,726 shares of the Company's common stock.

8-K filing: Eyenovia, Inc. entered into a securities purchase agreement with a single fundamentals-based healthcare investor for a registered direct offering of 3,223,726 shares of common stock at a price of $0.6204 per share, with aggregate gross proceeds expected to be approximately $2.0 million. ($2.0M proceeds)

10-K filing | 36.7M shares outstanding

10-Q filing | 40.1M shares outstanding

8-K filing: Eyenovia, Inc. entered into a securities purchase agreement to sell 4,198,633 shares of common stock, pre-funded warrants to purchase up to 2,252,979 shares of Common Stock and warrants to purchase up to 4,838,709 shares of Common Stock in a registered direct offering.

8-K filing: Eyenovia, Inc. entered into a license agreement with Formosa Pharmaceuticals, Inc., granting Eyenovia an exclusive license to commercialize a novel formulation of Clobetasol Proprionate in the United States, with half of the $2 million upfront payment to Formosa being in the form of 487,805 shares of Eyenovia's common stock.

10-Q filing | 38.1M shares outstanding

10-Q filing | 37.4M shares outstanding

10-K filing | 28.4M shares outstanding

S-3 filing: This prospectus relates to the offer and sale by the selling stockholders of up to 2,875,554 shares of common stock of Eyenovia, Inc. that have been issued or are issuable in connection with the Loan and Security Agreement.

8-K filing: Eyenovia, Inc. issued 219,123 shares of Common Stock to Avenue Venture Opportunities Fund, L.P. and 328,684 shares of Common Stock to Avenue Capital Management II, L.P. in connection with a Loan and Security Agreement.

10-Q filing | 28.4M shares outstanding

10-Q filing | 28.4M shares outstanding

10-Q filing | 30.0M shares outstanding

10-K filing | 26.3M shares outstanding

8-K filing: Eyenovia, Inc. entered into a securities purchase agreement for the issuance and sale of 3,000,000 shares of common stock, warrants to purchase 4,870,130 shares of common stock, and pre-funded warrants to purchase 1,870,130 shares of common stock at a price of $3.08 per share. ($15.0M proceeds)

S-3 filing: This S-3 filing is for a shelf offering of up to $100,000,000 in common stock, preferred stock, and debt securities, offered from time to time at prices and terms to be determined at the time of the offering.

10-Q filing | 26.1M shares outstanding

10-Q filing | 25.9M shares outstanding

10-Q filing | 25.9M shares outstanding

8-K filing: Eyenovia, Inc. entered into a Loan and Security Agreement and issued warrants to Silicon Valley Bank to purchase 91,884 shares of common stock at an exercise price of $4.76 per share.

10-K filing | 25.6M shares outstanding

10-Q filing | 24.9M shares outstanding

10-Q filing | 20.5M shares outstanding

10-Q filing | 19.8M shares outstanding

S-3/A filing: This prospectus relates to the resale from time to time of up to 2,675,293 shares of our common stock, and 1,337,659 shares of our common stock that are issuable upon the exercise of Class A warrants and 2,006,495 shares of our common stock that are issuable upon the exercise of Class B warrants held by the selling stockholders named in this prospectus.

S-3 filing: This prospectus relates to the resale from time to time of up to 2,675,293 shares of our common stock, and 1,337,659 shares of our common stock that are issuable upon the exercise of Class A warrants and 2,006,495 shares of our common stock that are issuable upon the exercise of Class B warrants held by the selling stockholders.

10-K filing | 19.8M shares outstanding